These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 23229379)
1. Lyophilized oral sustained release polymeric nanoparticles of nateglinide. Kaleemuddin M; Srinivas P AAPS PharmSciTech; 2013 Mar; 14(1):78-85. PubMed ID: 23229379 [TBL] [Abstract][Full Text] [Related]
2. Compatibility studies of nateglinide with excipients in immediate release tablets. Pani NR; Nath LK; Acharya S Acta Pharm; 2011 Jun; 61(2):237-47. PubMed ID: 21684850 [TBL] [Abstract][Full Text] [Related]
3. Formulation and in vitro evaluation of nateglinide microspheres using HPMC and carbopol-940 polymers by ionic gelation method. Bashir S; Nazir I; Khan H; Alamgeer ; Asad M; ul Hassnain F; Qamar S Pak J Pharm Sci; 2013 Nov; 26(6):1229-35. PubMed ID: 24191331 [TBL] [Abstract][Full Text] [Related]
4. Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. Makino C; Sakai H; Okano A; Yabuki A Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):907-13. PubMed ID: 19721250 [TBL] [Abstract][Full Text] [Related]
5. Enhanced dissolution and bioavailability of Nateglinide by microenvironmental pH-regulated ternary solid dispersion: in-vitro and in-vivo evaluation. Wairkar S; Gaud R; Jadhav N J Pharm Pharmacol; 2017 Sep; 69(9):1099-1109. PubMed ID: 28590055 [TBL] [Abstract][Full Text] [Related]
7. Effect of semicrystalline polymers on self-emulsifying solid dispersions of nateglinide: in vitro and in vivo evaluation. Swain RP; Subudhi BB Drug Dev Ind Pharm; 2018 Jan; 44(1):56-65. PubMed ID: 28845687 [TBL] [Abstract][Full Text] [Related]
8. Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets. Makino C; Ninomiya N; Sakai H; Orita H; Okano A; Yabuki A Chem Pharm Bull (Tokyo); 2006 Apr; 54(4):409-14. PubMed ID: 16595936 [TBL] [Abstract][Full Text] [Related]
9. I. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: nanoparticles and co-mixing. Maggi L; Bruni G; Maietta M; Canobbio A; Cardini A; Conte U Int J Pharm; 2013 Sep; 454(1):562-7. PubMed ID: 23867985 [TBL] [Abstract][Full Text] [Related]
10. In vitro characterization and invivo toxicity study of repaglinide loaded poly (methyl methacrylate) nanoparticles. Dhana Lekshmi UM; Poovi G; Kishore N; Reddy PN Int J Pharm; 2010 Aug; 396(1-2):194-203. PubMed ID: 20600729 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by PK/PD analysis in rats. Takanohashi T; Arisaka H; Ubukata K; Hayashi M; Yamada Y Eur J Drug Metab Pharmacokinet; 2012 Mar; 37(1):9-15. PubMed ID: 22012638 [TBL] [Abstract][Full Text] [Related]
12. Sustained antibacterial activity of doxycycline-loaded poly(D,L-lactide-co-glycolide) and poly(epsilon-caprolactone) nanoparticles. Misra R; Acharya S; Dilnawaz F; Sahoo SK Nanomedicine (Lond); 2009 Jul; 4(5):519-30. PubMed ID: 19572818 [TBL] [Abstract][Full Text] [Related]
13. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and characterization of carboxymethyl chitosan hydrogel: application as pH-sensitive delivery for nateglinide. Vaghani SS; Patel MM; Satish CS; Patel KM; Jivani NP Curr Drug Deliv; 2012 Nov; 9(6):628-36. PubMed ID: 22452405 [TBL] [Abstract][Full Text] [Related]
15. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects. Luzio SD; Anderson DM; Owens DR J Clin Endocrinol Metab; 2001 Oct; 86(10):4874-80. PubMed ID: 11600556 [TBL] [Abstract][Full Text] [Related]
17. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Kalbag JB; Walter YH; Nedelman JR; McLeod JF Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245 [TBL] [Abstract][Full Text] [Related]
18. Design, optimization and evaluation of poly-ε-caprolactone (PCL) based polymeric nanoparticles for oral delivery of lopinavir. Ravi PR; Vats R; Dalal V; Gadekar N; N A Drug Dev Ind Pharm; 2015 Jan; 41(1):131-40. PubMed ID: 24180260 [TBL] [Abstract][Full Text] [Related]